Efficacy and safety of statins for patients with chronic kidney disease
Not Applicable
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000005812
- Lead Sponsor
- ihon University School of Medicine, Nephrology, Hypertension and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients treated with dialysis therapy LDL cholesterol < 120 mg/d
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Kidney function (serum creatinine, estimated glomerular filtration rate, cystatin C), Urinary albumin or protein, Urinary 8-OHdG and L-FABP, Serum lipid profile
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie statin-induced kidney protection in chronic kidney disease?
How do statins compare to standard-of-care treatments in slowing CKD progression?
Which biomarkers correlate with statin efficacy in patients with stage 3-4 chronic kidney disease?
What are the key adverse events associated with statin use in renal impairment populations?
How do statin combinations with ACE inhibitors impact cardiovascular outcomes in CKD patients?